Medical Devices; Medical Device Reporting; Confirmation of Effective Date, 34652 [05-11786]
Download as PDF
<![CDATA[
34652
Federal Register / Vol. 70, No. 114 / Wednesday, June 15, 2005 / Rules and Regulations
normal business hours from our Help
line at (202) 502–8222 or the Public
Reference Room at (202) 502–8371 Press
0, TTY (202) 502–8659. E-Mail the
Public Reference Room at
public.referenceroom@ferc.gov.
Effective Date
11. These regulations are effective
immediately upon publication in the
Federal Register. In accordance with 5
U.S.C. 553(d)(3), the Commission finds
that good cause exists to make this Final
Rule effective immediately. It concerns
only a matter of internal operations and
will not affect the rights of persons
appearing before the Commission. There
is therefore no reason to make it
effective at a later time.
12. The provisions of 5 U.S.C. 801
regarding Congressional review of Final
Rules do not apply to this Final Rule,
because the rule concerns agency
procedure and practice and will not
substantially affect the rights of nonagency parties.
13. The Commission is issuing this as
a final rule without a period for public
comment. Under 5 U.S.C. 553(b), notice
and comment procedures are
unnecessary where a rulemaking
concerns only agency procedure and
practice, or where the agency finds that
notice and comment is unnecessary.
This rule concerns only matters of
agency procedure and will not
significantly affect regulated entities or
the general public.
List of Subjects in 18 CFR Part 375
Authority delegations (Government
agencies), Seals and insignia, Sunshine
Act.
By the Commission.
Linda Mitry,
Deputy Secretary.
In consideration of the foregoing, the
Commission amends part 375, chapter I,
title 18, Code of Federal Regulations, as
follows.
I
PART 375—THE COMMISSION
1. The authority citation for part 375
continues to read as follows:
I
Authority: 5 U.S.C. 551–557; 15 U.S.C.
717–717w, 3301–3432; 16 U.S.C. 791–825r,
2601–2645; 42 U.S.C. 7101–7352.
2. Section 375.307 is amended by
revising paragraphs (f)(3) and (k)(4) and
by adding paragraph (f)(4) to read as
follows:
I
§ 375.307 Delegations to the Director of
the Office of Markets, Tariffs and Rates.
*
*
*
*
*
(f) * * *
(3) Advise the filing party of any
actions taken under paragraph (f)(1) or
VerDate jul<14>2003
16:54 Jun 14, 2005
Jkt 205001
(f)(2) of this section and designate rate
schedules, rate schedule changes, and
notices of changes in rates, and the
effective date hereof; and
(4) Refer to the Chief Administrative
Law Judge (Chief ALJ), with the Chief
ALJ’s concurrence, uncontested interim
natural gas rate motions that would
result in lower rates, pending
Commission action on settlement
agreements.
*
*
*
*
*
(k) * * *
(4) Refer to the Chief Administrative
Law Judge (Chief ALJ), with the Chief
ALJ’s concurrence, uncontested interim
electric rate motions that would result
in lower rates, pending Commission
action on settlement agreements.
*
*
*
*
*
I 3. Section 375.311 is revised to read as
follows:
§ 375.311 Delegations to the Director,
Office of External Affairs.
The Commission authorizes the
Director, Office of External Affairs, or
the Director’s designee, to take all
actions required or permitted to be
taken by the Director under Secs.
388.108 through 388.110 of this chapter.
[FR Doc. 05–11553 Filed 6–14–05; 8:45 am]
BILLING CODE 6717–01–P
and Drug Administration, 1350 Piccard
Dr., Rockville, MD 20850, 301–827–
2983.
SUPPLEMENTARY INFORMATION: In the
Federal Register of February 28, 2005
(70 FR 9516), FDA solicited comments
concerning the direct final rule for a 75day period ending May 16, 2005. FDA
stated that the effective date of the
direct final rule would be on July 13,
2005, 60 days after the end of the
comment period, unless any significant
adverse comment was submitted to FDA
during the comment period. FDA
received 16 comments, 3 of which
supported the plain language revisions
and several of which requested further
revisions or substantive changes to the
medical device reporting rule. The
agency did not receive any significant
adverse comment on the plain language
revisions.
Authority: Therefore, under the Federal
Food, Drug, and Cosmetic Act, and under
authority delegated to the Commissioner of
Food and Drugs, notice is given that no
objections were filed in response to the
February 28, 2005, direct final rule.
Accordingly, the amendments issued thereby
are effective July 13, 2005.
Dated: June 9, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–11786 Filed 6–14–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
DEPARTMENT OF STATE
21 CFR Part 803
22 CFR Parts 120, 123, 124, 126, and
127
[Docket No. 2004N–0527]
[Public Notice 5108]
Medical Devices; Medical Device
Reporting; Confirmation of Effective
Date
AGENCY:
Food and Drug Administration,
HHS.
Direct final rule; confirmation of
effective date.
SUMMARY: The Food and Drug
Administration (FDA) is confirming the
effective date of July 13, 2005, for the
direct final rule that appeared in the
Federal Register of February 28, 2005
(70 FR 9516). The direct final rule
revised the medical device reporting
regulations into plain language in order
to make the regulations easier to
understand. This document confirms
the effective date of the direct final rule.
DATES: Effective date confirmed: July 13,
2005.
FOR FURTHER INFORMATION CONTACT:
Howard Press, Center for Devices and
Radiological Health (HFZ–531), Food
Frm 00026
Amendments to the International
Traffic in Arms Regulations: Various
Fmt 4700
Sfmt 4700
Department of State.
Final rule.
AGENCY:
ACTION:
ACTION:
PO 00000
Z–RIN 1400–ZA15
SUMMARY: The Department of State is
amending and/or clarifying the content
of a number of provisions of the
International Traffic in Arms
Regulations (ITAR). The affected parts
of the ITAR are: Part 120—Purpose and
Definitions; Part 123—Licenses for the
Export of Defense Articles; Part 124—
Agreements, Off-Shore Procurement and
Other Defense Services; Part 126—
General Policies and Provisions; and
Part 127—Violations and Penalties. See
SUPPLEMENTARY INFORMATION for a
description of the changes and
clarifications for each respective part.
DATES: Effective June 15, 2005.
ADDRESSES: Interested parties are
invited to submit written comments to
E:\FR\FM\15JNR1.SGM
15JNR1
]]>Agencies
[Federal Register Volume 70, Number 114 (Wednesday, June 15, 2005)]
[Rules and Regulations]
[Page 34652]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-11786]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 803
[Docket No. 2004N-0527]
Medical Devices; Medical Device Reporting; Confirmation of
Effective Date
AGENCY: Food and Drug Administration, HHS.
ACTION: Direct final rule; confirmation of effective date.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is confirming the
effective date of July 13, 2005, for the direct final rule that
appeared in the Federal Register of February 28, 2005 (70 FR 9516). The
direct final rule revised the medical device reporting regulations into
plain language in order to make the regulations easier to understand.
This document confirms the effective date of the direct final rule.
DATES: Effective date confirmed: July 13, 2005.
FOR FURTHER INFORMATION CONTACT: Howard Press, Center for Devices and
Radiological Health (HFZ-531), Food and Drug Administration, 1350
Piccard Dr., Rockville, MD 20850, 301-827-2983.
SUPPLEMENTARY INFORMATION: In the Federal Register of February 28, 2005
(70 FR 9516), FDA solicited comments concerning the direct final rule
for a 75-day period ending May 16, 2005. FDA stated that the effective
date of the direct final rule would be on July 13, 2005, 60 days after
the end of the comment period, unless any significant adverse comment
was submitted to FDA during the comment period. FDA received 16
comments, 3 of which supported the plain language revisions and several
of which requested further revisions or substantive changes to the
medical device reporting rule. The agency did not receive any
significant adverse comment on the plain language revisions.
Authority: Therefore, under the Federal Food, Drug, and Cosmetic
Act, and under authority delegated to the Commissioner of Food and
Drugs, notice is given that no objections were filed in response to
the February 28, 2005, direct final rule. Accordingly, the
amendments issued thereby are effective July 13, 2005.
Dated: June 9, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-11786 Filed 6-14-05; 8:45 am]
BILLING CODE 4160-01-S
